The pharmaceutical industry in South Korea and overseas has begun developing trispecific antibodies that bind three targets. Previously, these companies focused on bispecific antibodies, which can bind simultaneously to two different antigens or two antigenic epitopes on a single antigen.

Crossing the blood-brain barrier (BBB) can increase the drug permeability, especially for anticancer drugs. Multi-targeted antibodies have the advantage of crossing the BBB by target binding to receptors on the BBB surface.

Recently, more companies have begun developing multi-targeted antibodies by matching antibodies that bind to both antigens regulating immune cell activity and specific antigens on tumor